Oncolytics kicks off reovirus trial
Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.
Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.
Articles in this issue
Genetics opens new window on acute myeloid leukemia
Pralatrexate: Upfront Rx strategy for T-cell lymphoma
Who's News
Functional MRI boosts early staging of cervical cancer
Unseen bone lesions flare up on post-Rx NSCLC scans
Exercise jumpstarts quality of life in lung ca
Champions strikes deal with Concordia
Oncolytics kicks off reovirus trial
PET/CT picks up additional lesions not found on chest CT
Targeted therapies address hard-to-treat liver tumors
Should ADT be part of care for all patients with intermediate-risk prostate cancer?
ASTRO hosts IT project; ASCO weighs in on stimulus plan
Calculate, negotiate: Pay heed to your non-CMS fees
Breast tissue evaluation with fine-needle aspiration fast tracks cancer Rx planning
Investing in future generationsSharon Murphy, MD, views pediatric oncology as a chance to affect an entire lifetime.
Related Videos
Related Content
